Bone density after teriparatide in patients with or without prior antiresorptive treatment: One-year results from the EUROFORS study

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3117-3128

  Minne, Helmut ^a   Audran, Maurice ^b   Simões, Maria E ^c   Obermayer Pietsch, Barbara ^d   Sigurdsson, Gunnar ^e   Marín, Fernando ^f   Dalsky, Gail P ^f   Nickelsen, Thomas ^f,g  

^a Klinik 'Der Fürstenhof'   (Germany)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f ELI LILLY AND COMPANY   (United States)

^g Endocrinology   (Germany)

Author keywords

Antiresorptive therapy; Bone mineral density; Osteoporosis; Postmenopausal women; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; ETIDRONIC ACID; GESTAGEN; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ADULT; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; BRONCHITIS; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HEART ATRIUM FIBRILLATION; HISTORY; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLUENZA; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MUSCLE CRAMP; NAUSEA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VERTIGO; VITAMIN SUPPLEMENTATION; VOMITING;

AGED; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHEMOTHERAPY, ADJUVANT; EUROPE; FEMALE; FEMUR NECK; HIP; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NEOADJUVANT THERAPY; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE; TREATMENT OUTCOME;

EID: 57749170286     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802466595     Document Type: Article

References (36)

1. Stepan JJ, Alenfeld F, Boivin G, et al. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003;37:225-238 (Pubitemid 38175992)
2. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-173
3. Cosman F. Anabolic therapy for osteoporosis: parathyroid hormone. Curr Osteoporos Rep 2005;3:143-149
4. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703 (Pubitemid 41127277)
5. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113-121 (Pubitemid 46049523)
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-1541 (Pubitemid 26411651)
7. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-694 (Pubitemid 30808808)
8. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004;34:736-746 (Pubitemid 38393811)
9. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:855-864 (Pubitemid 43787992)
10. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-1768 (Pubitemid 41138965)
11. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244-1253 (Pubitemid 40863814)
12. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-1941 (Pubitemid 37377441)
13. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-1853 (Pubitemid 32911491)
14. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-543 (Pubitemid 36241071)
15. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005;36:948-958 (Pubitemid 40797995)
16. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
17. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-2030 (Pubitemid 39390560)
18. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-1513 (Pubitemid 41243539)
19. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-321
20. Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426-438 (Pubitemid 38998935)
21. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-860
22. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; published online 27 May 2008; doi:10.1359/jbmr.080506
23. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual X-ray absorptiometry: patient and phantom crosscalibration results. J Bone Miner Res 1994;9:1503-1514 (Pubitemid 24300099)
24. Hanson J. Standardization of femur BMD. J Bone Miner Res 1997;12:1316-1317
25. Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23 (Pubitemid 36008335)
26. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-751 (Pubitemid 41094385)
27. Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006;91:1370-1375
28. Gallagher JC, Rosen CJ, Chen P, et al. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006;39:1268-1275 (Pubitemid 44827926)
29. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215 (Pubitemid 37152030)
30. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-565
31. Graeff C, Timm W, Nickelsen TN, et al. Monitoring teriparatide- associated changes in vertebral microstructure by highresolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 2007;22:1426-1433 (Pubitemid 351339687)
32. Jakob F, Marin F, Martin-Mola E, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 2006;99:531-543 (Pubitemid 44304838)
33. Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006;21:1565-1570 (Pubitemid 44484601)
34. Díez-Pérez A, González-Macías J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 2008; June 11 (epub ahead of print)
35. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566-575 (Pubitemid 41138938)
36. Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone mineral density in men with osteoporosis. J Bone Miner Res 2003;18(1):9-17 (Pubitemid 36008334)